# A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

> **NCT01077622** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 10 (actual)

## Conditions studied

- Leukaemia, Lymphocytic, Chronic

## Interventions

- **DRUG:** ofatumumab 100 mg, 1000 mg / vial

## Key facts

- **NCT ID:** NCT01077622
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-01
- **Primary completion:** 2011-04-01
- **Final completion:** 2011-04-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01077622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01077622, "A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01077622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*